Stock Update (NASDAQ:GILD): Gilead Sciences to Release First Quarter 2016 Financial Results on Thursday, April 28, 2016

[Business Wire] – Gilead Sciences, Inc. announced today that its first quarter 2016 financial results will be released on Thursday, April 28, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2016 and provide a general business update. Read more on this. Gilead Sciences Inc. (GILD) , valued at $137.82B, started trading this morning at $99.91. Looking at the stock, its one day range is $99.90 to $101.84 with a one year range of $81.89 to $123.37. GILD shares are currently priced at 8.13x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -2.56x earnings multiple for the same period. The company pays shareholders $1.72 per share in dividend income per year, for a current yield of 1.73%. Consensus earnings for the current quarter by the 23 sell-side analysts covering the stock is an estimate of $3.13 per share, which would be $0.19 better than the year-ago quarter and a $0.14 sequential increase. What we find to be interesting is that the full-year EPS estimate of $12.31 is a $0.30 worse when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $8.08 Billion. If reported, that would be a 6.46% increase over the year-ago quarter. Recently, Citigroup Initiated GILD at Buy (Feb 25, 2016). Previously, Standpoint Research Initiated GILD at to Buy. When considering if perhaps the stock is under or overvalued, the average price target is $114.10, which is 14.20% above where the stock opened this morning. See more in (NASDAQ:GILD) Similar Articles: Stock Update (NASDAQ:GILD): Gilead Sciences to Release Fourth Quarter and Full Year 2015 Financial Results on Tuesday, February 2, 2016 Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Technical Scrutiny on Biotechnology Stocks — Gilead Sciences, Sarepta Therapeutics, Dyax Corp., and Baxalta Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences Announces Fourth Quarter 2015 Dividend